Suchergebnisse - "De Giorgi, Ugo"

PubPharm (29)

1

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma : Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Motzer, R. | Porta, C. | Eto, M. | +134

2

Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or Pazopanib

enthalten in: Clinical genitourinary cancer | 2024

von Catalano, M. | De Giorgi, U. | Bimbatti, D. | +9

3

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR) : extended follow-up from the phase 3, randomised, open-label study

enthalten in: The Lancet. Oncology | 2023

von Choueiri, T. | Eto, M. | Motzer, R. | +25

ErratumIn: Lancet Oncol. 2023 Apr;24(4):e146. - PMID 36990611

4

Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

enthalten in: JAMA oncology | 2022

von Motzer, R. | Powles, T. | Atkins, M. | +17

5

Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma

enthalten in: Cells | 2021

von Oudard, S. | Benhamouda, N. | Escudier, B. | +20

6

Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma : A Large, Multicenter, Prospective Trial

enthalten in: The oncologist | 2021

von Basso, U. | Facchinetti, A. | Rossi, E. | +20

7

Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features : A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial

enthalten in: European urology | 2021

von Rini, B. | Motzer, R. | Powles, T. | +17

CommentIn: Ann Transl Med. 2021 Jan;9(2):97. - PMID 33569399

8

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

enthalten in: The New England journal of medicine | 2021

von Motzer, R. | Alekseev, B. | Rha, S. | +136

CommentIn: N Engl J Med. 2021 Apr 8;384(14):1360-1361. - PMID 33616313

9

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer : Italian multicenter real world SAX study final results

enthalten in: Journal of translational medicine | 2019

von Facchini, G. | Rossetti, S. | Berretta, M. | +35

10

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

enthalten in: Journal of translational medicine | 2019

von Facchini, G. | Rossetti, S. | Berretta, M. | +35